Dermatology News and Research

Latest Dermatology News and Research

Strategies to reduce readmission are lacking in US hospitals

A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.

30 Jul 2012

Walking speed could explain high BP and mortality link in elderly

Elderly individuals with high systolic blood pressure who walk quickly have a higher mortality rate than their counterparts who walk more slowly, show US study results.

30 Jul 2012

Increased risk for AMI following hip- and knee-replacement surgery

Elderly patients are at a significantly increased risk for acute myocardial infarction in the 2 weeks following total hip- or knee-replacement surgery, research shows.

27 Jul 2012

Walking speeds the way to understanding elderly blood pressure

The first study to examine walking speed, mortality, and blood pressure has shown that frail, elderly adults who have high blood pressure may actually be at a decreased risk for mortality, write researchers in the Archives of Internal Medicine.

26 Jul 2012

Congenital long QT syndrome guidelines ‘too restrictive’

Athletes who choose to continue competing after being diagnosed with long QT syndrome have a low rate of LQTS-triggered cardiac events, US researchers report.

26 Jul 2012

New association found between basal cell carcinoma and eczema

In the powerful sunlight of July, newly published results from a large study of people at high risk for basal cell carcinoma support the emerging view of the nation's most common cancer as a chronic ailment that often repeatedly afflicts older people but for which the seeds may be planted in youth. The research also found a new association with eczema.

26 Jul 2012

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib—the current standard of care for this patient population.

26 Jul 2012

Hard work puts stress on the female heart

Women who have stressful jobs may be putting themselves at increased risk for a cardiovascular event a decade down the line, researchers say.

25 Jul 2012

Parental job type influences risk for birth defects

Certain professions increase the likelihood for men having children with birth disorders, shows research published in Occupational and Environmental Medicine.

25 Jul 2012

Low blood anticoagulant levels increase risk for VTE

Low plasma levels of antithrombin, protein C, and protein S significantly increase the risk for venous thromboembolism, Italian research shows.

25 Jul 2012

Latest polypill trial yields largest improvements yet

The results of the first trial to administer the polypill on the basis of age alone has shown the largest reductions in blood pressure and cholesterol level of any polypill trial to date, researchers report.

24 Jul 2012

Paramedics could up their game to meet reperfusion guidelines

Researchers say that Canadian guidelines for reperfusion in ST-segment-elevation myocardial infarction can only be met if electrocardiograms are administered by paramedics.

24 Jul 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer."

23 Jul 2012